Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "China"

501 News Found

China, South Korea, and India driving innovation in medical robotics in APAC, says GlobalData
News | January 16, 2023

China, South Korea, and India driving innovation in medical robotics in APAC, says GlobalData

APAC to see a reduction in imported surgical robotics


NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData
News | December 27, 2022

NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData

China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.


China aims to lead next bio revolution in advanced biologics, says GlobalData
News | December 15, 2022

China aims to lead next bio revolution in advanced biologics, says GlobalData

China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production


Lynparza approved in China as first-line maintenance treatment with Bevacizumab for HRD- positive advanced ovarian cancer
Drug Approval | September 23, 2022

Lynparza approved in China as first-line maintenance treatment with Bevacizumab for HRD- positive advanced ovarian cancer

One in two women with advanced ovarian cancer has an HRD-positive tumor


Ascletis announces IND approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA
Drug Approval | August 22, 2022

Ascletis announces IND approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA

Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA


Shivalik Rasayan Ltd inks marketing agreement with China Chinopharma
News | August 03, 2022

Shivalik Rasayan Ltd inks marketing agreement with China Chinopharma

The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.


Brii Bio inks partnership with China Resources Pharmaceutical to advance the commercialization of Long-acting COVID-19 neutralizing antibody therapy
Drug Approval | July 20, 2022

Brii Bio inks partnership with China Resources Pharmaceutical to advance the commercialization of Long-acting COVID-19 neutralizing antibody therapy

The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China


China Pharma submits plan of compliance to NYSE American
News | July 18, 2022

China Pharma submits plan of compliance to NYSE American

The company was directed to submit a plan of compliance by July 15, 2022


China medical devices market to surpass $42 billion in 2022: GlobalData
News | July 10, 2022

China medical devices market to surpass $42 billion in 2022: GlobalData

Domestic devices are usually preferred over imported medical devices in the national or regional procurement.


Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
News | July 01, 2022

Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China

Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia